…or discomfort; an accelerating pattern, with increasing frequency or severity; angina that awakens the patient from sleep. Patients receiving modified antiplatelet therapy require clinical surveillance…

…50% from baseline. In patients who experience a recurrent atherothrombotic or cardiovascular event within 2 years while receiving maximally tolerated statin based treatment, an LDL…

…Patients receiving medications that increase bleeding risk, including oral anticoagulants, clopidogrel, NSAIDs, or fibrinolytics. For patients with active bleeding requiring reversal of prasugrel's pharmacological…

…drug induced arrhythmias in patients receiving agents known to alter the electrical properties of the heart (inducing QRS or QT prolongation) or causing electrolyte abnormalities…

…fibrillation, particularly when other therapeutic options cannot be pursued. Patients receiving digoxin may present with symptoms of digitalis toxicity, which manifests across multiple organ systems…

…double blind, placebo controlled study of 13,970 patients at high cardiovascular risk who were unable or unwilling to take statins. Approximately 70% were in…

…specified by the guideline. PCSK9 inhibitors are also relevant in statin intolerant patients who remain above goal despite alternative lipid lowering therapy. Evolocumab and alirocumab…

…a 50% reduction from baseline. For a patient who experiences a recurrent atherothrombotic event while receiving maximally tolerated statin therapy, an LDL C goal below…

…lipoprotein(a) are variable or modest. In phase III studies involving patients with ASCVD or at least one ASCVD risk equivalent who were receiving statins…

…the patient is receiving a stable diuretic dose. Other clinical contexts Secondary causes should be pursued when abnormalities are identified on initial testing or when…